158 related articles for article (PubMed ID: 3237058)
1. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
[TBL] [Abstract][Full Text] [Related]
2. Relationship between metabolic phenotype of N-acetylation and bladder cancer.
Cui X; Guo R; Xu Z; Wang B; Li C
Chin Med J (Engl); 2000 Apr; 113(4):303-5. PubMed ID: 11775223
[TBL] [Abstract][Full Text] [Related]
3. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
[TBL] [Abstract][Full Text] [Related]
4. Hepatic acetylator phenotype in bladder cancer patients.
Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
[TBL] [Abstract][Full Text] [Related]
5. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
[TBL] [Abstract][Full Text] [Related]
6. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability factors of isoniazid in fast and slow acetylators, healthy volunteers.
Augustynowicz-Kopeć E; Zwolska Z
Acta Pol Pharm; 2002; 59(6):452-7. PubMed ID: 12669770
[TBL] [Abstract][Full Text] [Related]
8. Incidence of isoniazid acetylation phenotypes in North Indians.
Gupta RC; Nair CR; Jindal SK; Malik SK
Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):259-64. PubMed ID: 6746149
[TBL] [Abstract][Full Text] [Related]
9. [Determination of the N-acetyltransferase phenotype in urothelial cancer patients and healthy controls].
Sone M
Hinyokika Kiyo; 1986 Aug; 32(8):1085-92. PubMed ID: 3788733
[TBL] [Abstract][Full Text] [Related]
10. [Isoniazid acetylation in Gilbert's syndrome].
Pereira-Filho RA; Sevá-Pereira A; de Magalhães AF
Arq Gastroenterol; 1985; 22(4):172-5. PubMed ID: 3837656
[TBL] [Abstract][Full Text] [Related]
11. Acetylation phenotypes in patients with bladder carcinoma.
Bicho MP; Breitenfeld L; Carvalho AA; Manso CF
Ann Genet; 1988; 31(3):167-71. PubMed ID: 3265609
[TBL] [Abstract][Full Text] [Related]
12. [Acetylation phenotype as a biomarker of sensitivity to the carcinogenic effect of aromatic amines].
Indulski JA; Krajewska B; Lutz W
Med Pr; 1992; 43(5):427-35. PubMed ID: 1293477
[TBL] [Abstract][Full Text] [Related]
13. [Antitubercular agents: pharmacogenetic factors in the development of adverse effects].
Ligueros M; Saavedra H; Neira S; Cruz-Coke R; Saavedra A; Kramer V; Gelman M; Nuñez A; Prieto JC
Rev Med Chil; 1990 Jul; 118(7):727-35. PubMed ID: 2131519
[TBL] [Abstract][Full Text] [Related]
14. [Phenotypic changes in acetylation in tumor patients].
Bulovskaia LN; Blinov NN; Simonov NN; Krupkin RG; Kolosov AI
Vopr Onkol; 1978; 24(10):76-9. PubMed ID: 716322
[TBL] [Abstract][Full Text] [Related]
15. Isoniazid acetylation phenotyping in Saudi Arabs.
Matar KM; Mayet AY; Ayoola EA; Bawazir SA; Al-Faleh FZ; Al-Wazzan A
J Clin Pharm Ther; 2004 Oct; 29(5):443-7. PubMed ID: 15482388
[TBL] [Abstract][Full Text] [Related]
16. N-acetyltransferase phenotype of patients with cancer of the larynx.
Drózdz M; Gierek T; Jendryczko A; Pilch J; Piekarska J
Neoplasma; 1987; 34(4):481-4. PubMed ID: 3658048
[TBL] [Abstract][Full Text] [Related]
17. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe.
William BM; Abdel-tawab AM; Hassan EA; Mohamed OF
Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499
[TBL] [Abstract][Full Text] [Related]
18. [Genetic polymorphism of isoniazid acetylation in Chilean patients with tuberculosis].
Ligueros M; Cruz Coke R; Neira S; Saavedra H; Kramer V; Prieto JC; Gelman M; Saavedra A; Nuñez A; Pescio S
Rev Med Chil; 1989 Dec; 117(12):1339-43. PubMed ID: 2519370
[TBL] [Abstract][Full Text] [Related]
19. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
Ylitalo P; Auterinen L; Marttinen A; Koivula T
Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
[TBL] [Abstract][Full Text] [Related]
20. [Acetylation phenotype as a risk factor of diabetic neuropathy].
Miarka J; Jonderko G; Straszecka J; Lachowicz B
Przegl Lek; 1990; 47(4):385-8. PubMed ID: 2217853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
